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Preferences Beyond HbA1c Measures
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Abstract
Background:Adjunct therapy can help patients with type 1 diabetes achieve glycemic goals while potentially mitigating
some of the side effects of insulin. In this study, we used a patient survey to identify the unmet needs in type 1 diabetes
therapy, patient views of treatment benefit–risk trade-offs, and patient preferences for the use of an adjunct therapy.
Methods: A quantitative survey was sent to 2084 adults with type 1 diabetes in November 2017. ‘‘Jobs-to-be-
done’’ and conjoint analyses were performed on survey responses to identify unmet needs and the importance of
treatment-associated benefits and risks to patients. A 5-point Likert scale measured the importance and satis-
faction with patients’ current therapy, and with gaps relating to unmet needs. In the conjoint analysis, patients
were asked to choose between ‘‘packages’’ of attributes of two doses of adjunct therapy (200 and 400 mg) and
placebo, based on established benefits and side effects.
Results: A total of 1313 patients (63%) responded. The greatest unmet needs identified were simplifying treatment,
lowering/maintaining glycated hemoglobin (HbA1c), reducing mental effort, and increasing time in range (TIR).
Conjoint analysis showed that reductions in body weight and TIR had the highest attribute importance (25% and 18%,
respectively). The majority (93%) of patients had a preference for the adjunct therapy (either dose) over placebo.
Conclusions: This survey highlights the importance of measures beyond HbA1c, such as treatment simplification
and TIR, and patient preference for adjunct therapies that help address unmet needs in type 1 diabetes treatment.
Keywords: Survey, Patient-reported outcomes, Treatment.
Introduction
Type 1 diabetes affects not only glycemic control butalso many aspects of a patient’s life, including emotional
well-being, quality of life, working ability, and social inter-
actions.1–3 Patients with type 1 diabetes are dependent on
insulin-replacement therapy, requiring multiple daily injec-
tions of insulin or a continuous subcutaneous insulin infusion
pump. In addition, monitoring of blood glucose using mul-
tiple daily finger-stick measurements or continuous glucose
monitoring (CGM) is recommended for better glycemic
control.4 Developments in insulin therapy and technology
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over recent decades include pens, inhaled insulin, long-acting
basal insulins (such as glargine 300 U/mL and degludec),
faster-acting prandial insulins, pramlintide, pumps, and
CGM. Despite these continued advances in management,
particularly in the types of devices available, type 1 diabetes
remains a constant daily burden for patients. Only an esti-
mated one in five children and one in three adults with type 1
diabetes in the United States reach glycated hemoglobin
(HbA1c) targets,5 and many still face issues with hypogly-
cemia. Real-world studies have estimated that most indi-
viduals with type 1 diabetes experience approximately two
episodes of nonsevere hypoglycemia each week, and one
severe event per patient per year.6 In addition, an estimated
two-thirds of patients with type 1 diabetes are overweight or
obese, leading to an increased risk of complications, such as
hypertension, dyslipidemia, and cardiovascular disease,
compared with healthy-weight individuals.7–9
In recent years, other agents already approved for treat-
ment of type 2 diabetes, such as metformin, glucagon-like
peptide-1 receptor agonists, and sodium/glucose cotransporter
(SGLT) inhibitors, have been investigated for their use as
adjunct therapy to insulin for type 1 diabetes.4 The goals of
adjunct therapy include helping patients with type 1 diabetes
achieve glycemic targets, lowering the risk of hypoglycemia,
reducing weight, improving quality of life, and increasing
time in range (TIR).10 While adjunct therapies have shown
beneficial effects in these various categories, some safety
concerns remain. For example, SGLT inhibitors are associated
with an increased risk of diabetic ketoacidosis (DKA)11;
therefore, health care providers and patients need to weigh up
the potential benefits and risks before considering these ther-
apies in their treatment regimen.
When navigating the risk–benefit ratio, it is important to
realize that patients’ and health care providers’ views may
differ on the importance of individual risk and benefit factors.12
In general, there is a lack of data on how patients perceive the
addition of adjunct therapies to their current regimens. There-
fore, market research tools, such as ‘‘jobs-to-be-done’’ and
conjoint analysis, are increasingly used to shed light on unmet
needs and patient preferences, helping health care providers in
the decision-making on the most appropriate treatments for
their patients.13–15 In this article, we describe the outcomes of
a patient survey, using the widely used ‘‘jobs-to-be-done’’
market research technique to uncover unmet needs (and thus
identify jobs that need to be done) in the current type 1 diabetes
therapy, and conjoint analysis to identify how patients viewed
the trade-offs between benefits and side effects, and whether
they would have a preference for use of an adjunct therapy.
Research Design and Methods
Qualitative assessment before the survey
Before the quantitative survey, and in accordance with best
practice on the use of conjoint analysis for the study of patient
preferences,16,17 two qualitative research exercises were used
to build a deeper understanding of the patient experience and
to select the most appropriate language for the questionnaire,
by identifying the terms that patients were most familiar with.
The first exercise was an online conversation with 50 par-
ticipants from an existing online community, which took
place over 3 days in October 2017 in the United States. The
second exercise was a series of five live in-depth interviews
with small groups of patients with type 1 diabetes (two or
three per interview), carried out at a market research facility
in October 2017 (New York). The online conversations were
to assess the main burdens of diabetes at four different levels:
(1) medical (e.g., day-to-day treatment and management of
diabetes and related complications); (2) logistical (burden
associated with the use of medical device and consumables);
(3) financial (out-of-pocket costs, private insurance, etc.);
and (4) emotional (stress associated with the disease); and
interviews were assessed qualitatively and used to test and
refine the terminology that would then be used in the quan-
titative survey.
Patients and study design
The quantitative survey was carried out in November 2017
by dQ&A Market Research, Inc. The market research
company sent an online survey to 2084 members with type 1
diabetes of its opt-in U.S.-based patient research panel for
ongoing research on opinions of patients with diabetes. Pa-
tients included in the panel were recruited from established
type 1 diabetes communities. The bona fide status of patients
was confirmed by their responses in previous surveys.
Patients included in the survey were diagnosed with type 1
diabetes; living in the United States; aged 18 years or older;
and had recently completely one of the dQ&A quarterly
surveys which are sent regularly to all patients on the panel.
Respondents received a nominal compensation (USD 10)
for completing the survey, although this was not mentioned
when they were initially recruited to the panel. The survey
was blinded; the participants were not given any informa-
tion on the study sponsor, product, or company names. The
study sponsor was not given information on the identity of
the participants.
Quantitative survey analysis
The survey had three distinct elements: characterization of
the survey respondents; jobs-to-be-done analysis (identifying
unmet needs); and conjoint analysis (assessment of patient
preferences). In accordance with current market research
best practice, all incomplete responses; surveys completed
in an unrealistically short time; and all responses with ran-
domly typed or nonsensical write-in responses to open-end-
questions were removed, to produce a final validated data
set. Statistical significance testing for all analyses of survey
responses was performed at the 90% confidence level.
Characterization of survey respondents
Characterization of the survey respondents included col-
lection of demographic data, self-reported diabetes outcomes,
complications, comorbidities, estimated time (minutes/day)
spent managing diabetes, height, weight, hypoglycemia
awareness, use of CGM, and currently used insulin-delivery
method. These characteristics were identified as important,
based on responses from previous surveys, and updated by
the respondents during the current survey.
Unmet patients’ needs analysis
The jobs-to-be-done analysis is a widely used tool in
market research to uncover and measure unmet needs.
The survey included the following 15 outcomes that patients
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were least satisfied with from a list of 44 outcomes used in
a previous dQ&A survey18: postprandial blood glucose
<180 mg/dL; overnight blood glucose 70–130 mg/dL; blood
glucose during the day 70–180 mg/dL; morning (fasting)
blood glucose 70–180 mg/dL; HbA1c reduced or maintained
at target; prevention of stress and anxiety caused by diabetes
(‘‘diabetes distress’’); prevention of weight gain; prevention
of hypoglycemic events not requiring medical assistance;
prevention of severe hypoglycemic events requiring medical
assistance; prevention of negative impact of diabetes on
family and loved ones; general well-being throughout the
day; simple and predictable diabetes management; reduced
mental effort needed to manage diabetes; prevention of
feelings of isolation and stigma due to diabetes; and flexi-
bility with exercise and diet.
A five-level ‘‘Likert scale’’ was used to measure the im-
portance (1 [not at all important] to 5 [extremely important])
and the degree of satisfaction (1 [not at all satisfied] to 5
[extremely satisfied]) of the outcomes from their current
therapy. Importance and satisfaction scores were calculated
as the percentage of respondents selecting the score of 4 or 5
on the Likert scale in importance and satisfaction of each
outcome, respectively. This percentage was converted to a
numerical score from 0 to 10 (with 100% being a score of 10).
To rank the unmet needs relative to each other, an ‘‘unmet
needs score’’ was calculated based on the importance and
satisfaction scores, and the ‘‘gap’’ between them, using the
following formula:
Unmet needs score¼ Importance score
þðImportance score Satisfaction scoreÞ:
The unmet needs score was used to identify the opportu-
nities for improvement on the current treatment, with a score
>10 indicating that needs are not currently being met effec-
tively (higher scores indicate a bigger unmet need).
Conjoint analysis of patient preference
To uncover preferences and simulate the real-world
decision-making process, that is, consideration of trade-offs
between benefits and side effects, a discreet-choice research
technique called conjoint analysis was used. This method is
used to avoid asking separately about individual preferences
for specific benefits or side effects,16,17 given that a rational
response would be to seek to maximize all available benefits
and reject all possible side effects. Using conjoint analysis,
participants were presented with pairwise choices of ‘‘pack-
ages’’ of drug attributes (i.e., benefits or side effects) for se-
lection. Each attribute was given various levels; for example,
the effect on time in the ideal glucose range could be 20 min
more, 1 h more, or 2.5 h more per day.
In this study, the packages considered by respondents were
drawn from outcomes of clinical trials of an SGLT adjunct
therapy (sotagliflozin). Participants were presented with nine
pairwise choices of packages, each consisting of attributes
drawn from the outcomes of the placebo (insulin only), the
200 mg, and the 400 mg doses. Each package was made up of
the following 10 attributes: reduction in HbA1c; reduction in
rapid-acting insulin dose required for meals; increased time
in the ideal blood glucose range; impact on weight; reduction
in systolic blood pressure; impact on hypoglycemic events;
risk of severe hypoglycemia; risk of DKA; risk of yeast in-
fection; and risk of diarrhea. Different levels within each
attribute representing the outcomes of the clinical trials were
used as part of the conjoint analysis (see Supplementary
Table S1). Note that levels and attributes can be positive
(a benefit) or negative (a side effect). As part of the conjoint
analysis, an underlying ‘‘utility’’ value was calculated for
each level for each attribute. Utility scores were then summed
to form specific packages that reflect the placebo, the 200 mg,
and the 400 mg doses. The utilities were summed to calculate
the patient ‘‘preference share,’’ which was used to compare
respondent preference for the three packages analyzed (pla-
cebo, 200 mg dose, and 400 mg dose). The relative impor-
tance of individual attributes to the respondents (summing to
100%) was also calculated as part of the analysis. Differences
between importance scores were tested for statistical signif-
icance at the 90% confidence level and categorized into tiers,
with no significant difference within tiers. Data were ana-
lyzed for all survey respondents, and for individual groups of
respondents based on the characteristics gathered in the first
part of the survey.
Willingness to take an oral medication
Participants’ willingness to take an oral medication, in
addition to optimized insulin therapy, was also analyzed.
Survey participants were given a choice of ‘‘definitely,’’
‘‘likely,’’ ‘‘unlikely,’’ or ‘‘definitely not’’ to the question
whether they would be willing to take a pill to help manage
their diabetes. Responses were analyzed for the overall
group, and based on the number of pills (0, 1–3, or ‡4) per day
the participants were taking at the time of the survey.
Results
Characterization of patients and demographics
In total, 1313 (63%) of the 2084 participants, aged 20–86
years, who were contacted returned a valid completed survey.
Baseline characteristics of the respondents are shown in
Table 1. Twenty percent of the respondents were aged ‡65
years (Supplementary Fig. S1). The majority of respondents
(78%) used an insulin pump rather than multiple daily in-
jections. Most of the CGM users also used an insulin pump
(715/806; 89%) (Supplementary Fig. S1). The frequency of
self-monitored blood glucose tests was higher in non-CGM
users (median 6 tests/day) compared with CGM users (me-
dian 4 tests/day) and ranged from not testing every day to ‡10
tests per day in both groups. At the time of survey, 58% of
respondents self-reported an HbA1c of <7.0% (<53 mmol/-
mol), 31% had an HbA1c between 7.0% (53 mmol/mol) and
8.0% (64 mmol/mol), and 11% of respondents reported an
HbA1c of >8.0% (>64 mmol/mol). The time spent managing
diabetes varied between CGM and non-CGM users, but no
clear trends were observed by age group or in association
with HbA1c or TIR (Supplementary Fig. S2).
Unmet needs (jobs-to-be-done) analysis
Twelve of the 15 outcomes had opportunity scores greater
than 10, indicating that these are significant unmet needs in
type 1 diabetes with a large gap between importance and
satisfaction (Fig. 1). Overall, the greatest opportunities for
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improving on current treatment in type 1 diabetes were in
simplifying treatment (score of 13.6), lowering or maintain-
ing HbA1c (score of 13.5), reducing mental effort (score of
13.2), and increasing TIR (70–180 mg/dL; score of 13.2).
Some variation across respondent groups was observed.
For example, lowering/maintaining an HbA1c of <7.0%
(53 mmol/mol) was identified as the most important un-
met need for the two groups of patients with an HbA1c
above target (7.0%–8.0% [53–64 mmol/mol], and >8.0%
[>64 mmol/mol]) with scores of 15.4 and 18.0, respectively. In
contrast, in the group of respondents with an HbA1c of <7.0%
(53 mmol/mol), lowering/maintaining HbA1c received a score
of only 11.5 (Supplementary Table S2). Preventing weight
gain had a higher unmet needs score in the group that said they
would like to lose weight (score of 15.9) compared with
those who did not feel that they would like to lose weight
(score of 2.3) (Supplementary Table S2). On average,
CGM users reported higher unmet needs scores than those
not using CGM. For CGM users, the highest unmet needs
scores were for treatment simplification (14.1 vs. 12.7 of
non-CGM users), reducing mental effort, and improv-
ing TIR, whereas for non-CGM users, the greatest unmet
need was lowering or maintaining HbA1c (Supplementary
Table S2).
Conjoint analysis
Across all respondents, weight reduction had the highest
attribute importance (25%), followed by TIR of blood glu-
cose 70–180 mg/dL (18%) (Fig. 2). Reduction in HbA1c and
yeast infections was ranked third in attribute importance
(12% and 11%, respectively), followed by diarrhea (9%) and
DKA (7%). Hypoglycemia was ranked together with a re-
duction in blood pressure as least important, with only 3%
importance value. The results were generally consistent
across all respondent subgroups (Supplementary Table S3).
However, the risk of yeast infection was statistically less
important to male than female respondents (9% vs. 12%).
Among respondents who reported a need to lose weight,
change in weight had the highest importance (27%), whereas
weight change was significantly less important (18%) to re-
spondents who reported not having the need to lose weight.
The analysis also showed that the majority of respondents
(93%) preferred the addition of the adjunct therapy (200 or
400 mg) over the placebo. Considered individually, the
200 mg dose had higher shares of preference (93%) than the
400 mg dose (86%) when compared with placebo (insulin-
only therapy) (Fig. 3). However, when the 200, 400 mg, and
placebo doses were compared at the same time, 73% of
Table 1. Demographic Data and Clinical Characteristics of Survey Respondents
Characteristics Respondents (n= 1313)
Female 880 (67)
Median age (range), years 53 (20–86)
18–34 155 (12)
35–49 396 (30)
50–64 497 (38)
‡65 265 (20)
Median diabetes duration (range), years 30 (2–75)
Mean BMI, kg/m2 27.4
HbA1c
<7% (<53 mmol/mol) 736 (58)
7%–8% (53–64 mmol/mol) 401 (31)
>8% (>64 mmol/mol) 138 (11)
Time in ideal blood glucose range, %
0–19 4
20–39 15
40–59 34
60–79 33
80–100 14
Insulin delivery method
Pump 1023 (78)
MDI 290 (22)
CGM use
Yes 806 (61)
No 507 (39)
Most common comorbidities, %a
High blood pressure 30
High cholesterol or triglycerides 30
Hypothyroidism or underactive thyroid 29
Depression 17
Diabetes-related eye problems 13
Unless stated otherwise, data are expressed as number of patients (%).
aIncludes comorbidities with a prevalence of >10%.
BMI, body mass index; CGM, continuous glucose monitoring; HbA1c, glycated hemoglobin; MDI, multiple daily injections.
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FIG. 1. Jobs-to-be-done opportunity scores for each of the 15 unmet needs analyzed. Unmet needs score was calculated as
follows: Importance score + (Importance score - Satisfaction score). Unmet needs scores ‡10 indicate important needs that
are not being met effectively or at all and scores <10 indicate needs that either are not important or being met effectively.
HbA1c, glycated hemoglobin.
FIG. 2. Most important attributes from conjoint analysis (n= 1313). Green and red segments represent benefits and side
effects of sotagliflozin, respectively. HbA1c, glycated hemoglobin.
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respondents indicated a preference for the 400 mg dose, with
the 200 mg dose receiving 20% preference share (Fig. 3).
Willingness to take oral medication
In total, 77% of respondents indicated that they were al-
ready taking at least one oral medication daily in addition to
insulin therapy at the time of the survey. Significantly more
patients already taking one or more pills per day (any med-
ication) indicated that they ‘‘definitely’’ would take a pill to
help better manage their diabetes compared with those not
taking any pills with their current therapy (Supplementary
Table S4). Similarly, a higher percentage of participants not
taking pills at the time of the survey indicated that they were
‘‘unlikely’’ or ‘‘definitely would not’’ take pills (16%)
compared with those who are already taking 1–3 pills/day
(9%) or ‡4 pills/day (6%) (Supplementary Table S4).
Discussion
These analyses identified 12 needs that are not adequately
met by current treatment for patients with type 1 diabetes.
Not surprisingly, HbA1c measures ranked highly in both the
unmet needs analysis and the conjoint analysis. Interestingly
though, many of the most important needs and preferences
identified were measures beyond HbA1c, such as improve-
ment in TIR, weight reduction, and reducing mental effort.
The results of this survey highlight patients’ desire to sim-
plify management of type 1 diabetes treatment, prevent
weight gain (a common problem with insulin therapy), and
improve or achieve greater TIR. Overall, 93% of respondents
would consider adding the adjunct therapy to insulin to help
address some of these unmet needs.
While the majority of attributes were similar between the
different patient groups, some opportunities for improvement
on the currently available treatment varied in importance
across patient groups. As expected, reducing HbA1c was
much more important in the groups not at HbA1c target (i.e.,
those with an HbA1c of >7.0% [>53 mmol/mol]) than those
who were already at target HbA1c levels. Similarly, pre-
venting weight gain/losing weight was much more important
to those respondents who would like to lose some weight than
to those who did not feel that they needed to. Interestingly,
prevention of hypoglycemia and severe hypoglycemia was
identified as lower priority unmet needs. This may be related
to the high percentage of respondents who were CGM users,
as they may feel less concerned about hypoglycemia risk due
to low blood glucose alerts and alarms provided by the de-
vice. DKA was given a low importance score, despite its
potentially serious consequences. The survey outcomes
suggest that while there is some level of awareness around
this issue, the majority (69%) of respondents had not expe-
rienced DKA since being diagnosed and 30% did not test
ketones on a regular basis (data not shown), which is similar
to findings from other questionnaires.19 The lower impor-
tance of both hypoglycemia risk and DKA also highlights a
possible educational gap in patients with type 1 diabetes,
which might help to improve their diabetes management,
glycemic variability, and overall well-being. The education
of patients about DKA may be especially important for those
who have SGLT2s added to their treatment regimens, given
their potential association with increased rates of DKA.20
Conjoint analysis also indicated that change in body
weight and TIR were considered the most important drivers
of patient preference, as with the jobs-to-be-done opportunity
scoring. All respondents were concerned about TIR, regard-
less of whether they were CGM users or not. However, pump
users were also more concerned about TIR than patients who
used multiple daily injections. Overall, simplification of
treatment was considered the greatest opportunity for im-
provement on current treatments, even in the groups of pa-
tients who used insulin pumps and CGM. In agreement with
the drivers of patient preference identified in the conjoint
FIG. 3. Comparison of preferences of respondents for the 200 mg dose adjunct therapy versus placebo, the 400 mg adjunct
therapy versus placebo, and for all three packages. CGM, continuous glucose monitoring; DKA, diabetic ketoacidosis;
HbA1c, glycated hemoglobin; MDI, multiple daily injections.
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analysis, the survey respondents had a strong preference for
use of the adjunct therapy with sotagliflozin (after evaluation
of the risk–benefit profile, more than 90% of respondents
would consider use of the adjunct therapy), which has dem-
onstrated weight loss and increased TIR in patients with type
1 diabetes, despite the increased risk of DKA.21–23
There were a number of limitations to this study. First, the
outcomes (benefits and risks) considered were taken from
clinical trials, rather than real-world evidence, and therefore
may not be completely representative of clinical practice
experience. Second, as mentioned above, more than half the
patients included had achieved target HbA1c levels, which is
considerably higher than the estimates of 14%–30% from
public registries.24 This may limit the direct application of the
results to the broader U.S. population of patients with type 1
diabetes. In addition, the higher proportion of patients al-
ready at target and over 65 years of age may have reduced
the importance of HbA1c reduction and hypoglycemia risk
compared with younger patients and those with poor gly-
cemic control. Finally, as these data were obtained from an
e-mail survey, the results may be subject to self-selection bias.
Despite these limitations, the high response rate to the survey
and consistency in responses indicated that many patients with
type 1 diabetes are not satisfied with their current treatment
options and are willing to consider adjunct therapies, despite
the potential increased risks of these therapies.
Conclusions
This survey highlights that there are still many unmet
needs in type 1 diabetes, including achievement of glycemic
control targets (HbA1c <7% [<53 mmol/mol]), prevention of
weight gain, increased time spent in the optimal blood glu-
cose range, and a desire for simpler diabetes management.
The benefits of new adjunct therapies appear to be aligned
with some of these needs, as more than 90% of respondents
would consider taking the medication evaluated in this sur-
vey, after appraising its risk–benefit profile.
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